Skip to main content
Log in

Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease

  • Original Articles
  • Published:
Blut Aims and scope Submit manuscript

Summary

A heat-treated factor VIII (F VIII) concentrate (Haemate P) has been administered to patients with various types of von Willebrand's disease (vWD). The 4 activities of F VIII/vWF as well as change in the multimeric structure of vWF were then studied. In 4 patients with type I vWF who were given a Ristocetin cofactor (Rcof) dose of 42–78 U/kg, there was a clear reduction of the bleeding time and an increase of F VIII:C, F VIII:Ag, Ag, Rcof and vWF: Ag for several hours. The recovery of Rcof. after 1 h was 50–75%. Although the multimeric composition of vWF in these patients was similar to that of normal plasma, the density of each multimer band was very low. After infusion, however, the density of all multimer bands increased for several hours, to decrease again after 24 h. In 4 patients with type II A vWD who received a dose of Rcof of 55–76 U/kg, the 4 activities of F VIII/vWF increased similarly as was the case in type I. All patients had only 3–4 smaller multimer bands. New larger and intermediate multimers appeared for several hours after infusion of the preparation. Two patients with type III vWD who received doses of Rcof of 52 and 65 U/kg showed also a similar increase in the 4 activities of F VIII/vWF after infusion. All the multimers lacking in these patients appeared for several hours after infusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Green D, Potter EV (1976) Failure of AHF concentrate to control bleeding in von Willebrand's disease. Am J Med 60: 357–360

    Google Scholar 

  2. Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR (1976) Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA 236: 2770–2772

    Google Scholar 

  3. Nilsson IM, Hedner U (1977) Characteristics of various factor VIII concentrates used in treatment of hemophilia A. Br J Haematol 37: 543–557

    Google Scholar 

  4. Yoshioka A, Shima M, Nishino M, Yoshikawa N, Fukui (1987) In vitro characterization of various heat-treated factor VIII concentrates. Arzneimittelforsch 37: 753–756

    Google Scholar 

  5. Hardisty RM, Macpherson JC (1962) A one-stage factor VIII (anti-hemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diathes Haemorrh 7: 215–229

    Google Scholar 

  6. Peake IR, Bloom AL, Giddings JC, Lundlam CA (1979) An immunoradiometric assay for procoagulant factor VIII antigen: Results in haemophilia, von Willebrand's disease and fetal plasma and serum. Br J Haematol 42: 269–281

    Google Scholar 

  7. Takase T, Yoshikawa N, Ueki K, Okamoto Y, Yasui M, Fukui H (1982) Determination of von Willebrand factor activity using RIPA-testkit (in Japanese), Shinryo-Shinyaku (Japanese Journal) 19: 3097–3101

    Google Scholar 

  8. Laurell C-B (1966) Quantitative estimation of protein by electrophoresis in agarose gel containing antibodies. Anal Biochem 15: 45–52

    Google Scholar 

  9. Ruggeri ZM, Zimmerman TS (1980) The complex multimeric composition of factor VIII/von Willebrand factor. Blood 57: 1140–1143

    Google Scholar 

  10. Rouzioux C, Chamaret S, Montagnier L, Carnelli V, Rolland G, Mannucci PM (1985) Absence of antibodies to AIDS virus in haemaphiliacs treated with heat-treated factor VIII concentrate. Lancet I: 271–272

    Google Scholar 

  11. Allain JP, Masson PI, Dolkart RE (1985) The case for heattreated products. Lancet I: 814–815

    Google Scholar 

  12. Mösseler J, Schimpf K, Auersward G, Bayer H, Schneider J, Hunsmann G (1985) Inability of pasteurised factor VIII preparations to induce antibodies to HTLV-III after long-term treatment. Lancet I: 1111

    Google Scholar 

  13. Abe T, Ikematsu S, Kamiya T, Kinoshita T, Nagao T, Nakamura K, Hiyoshi Y, Fukui H, Fukutake K, Mimaya J, Mori K, Yoshida Y (1985) Clinical evaluation of factor VIII concentrate (BI 8021) (in Japanese). Shinryo-Shinyaku (Japanese Jornal) 22: 1889–1916

    Google Scholar 

  14. Köhler M, Hellstern P and Wenzel E (1985) The Use of Heat-Treated Factor VIII-Concentrates in von Willebrand's Disease. Blut 50: 25–27

    Google Scholar 

  15. Fukui H, Takase T, Tokuda S, Murashima N, Okuda T, Kamitsuji H, Mikami S, Yoshioka A (1978) Infusion with factor VIII concentrates in patients with von Willebrand's disease: Studies of von Willebrand factor, factor VIII-related antigen and factor VIII procoagulant activity. J Nara Med Ass 29: 117–128

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fukui, H., Nishino, M., Terada, S. et al. Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease. Blut 56, 171–178 (1988). https://doi.org/10.1007/BF00320748

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00320748

Key words

Navigation